Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT06101745

Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

Led by Curadel Surgical Innovations, Inc. · Updated on 2026-02-23

336

Participants Needed

10

Research Sites

109 weeks

Total Duration

On this page

Sponsors

C

Curadel Surgical Innovations, Inc.

Lead Sponsor

L

Leiden University Medical Center

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to determine if the drug Nizaracianine Triflutate can help surgeons see and avoid the ureters during abdominopelvic surgery. The ureters are thin-wall, collapsible tubes that connect the kidneys to the bladder. They are difficult to see during surgery and are sometimes damaged accidentally. The main questions to answer are: 1) is this drug safe for use in patients undergoing abdominopelvic surgery and 2) can the drug see the ureters while simultaneously providing information about how well they are working. The clinical trial has 3 parts. Surgery patients enrolled in the first part (Phase 2) will receive drug at different doses to determine the best dose. Patients enrolled in the second part (Phase 3A) will be randomly assigned to drug or placebo (sugar), at the best dose from Phase 2, so the two can be compared directly. Patients enrolled in the final part (Phase 3B) will all receive drug at the best dose from Phase 2.

CONDITIONS

Official Title

Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age ≥ 18 years old
  • Scheduled to undergo a medically necessary abdominopelvic surgical procedure expected to last ≥ 2 hours (Phase 2) or any duration (Phase 3), during which one or more ureters should be visualized during the procedure. All abdominopelvic surgical procedures are eligible unless specifically excluded in the Exclusion Criteria.
  • For Phase 2, the procedure must require identification of one or both ureters using dissection, mobilization, or other surgical means.
  • The planned surgical procedure is open or minimally invasive surgery (MIS), including robotic.
  • Both ureters are expected to be present and functional.
  • Capable and willing to provide informed consent prior to study-specific procedures
  • Screening laboratory test results are within normal limits, or if any are outside of normal limits, they are considered by the site PI, and confirmed by the lead PI, to be clinically insignificant.
  • Negative pregnancy test in women of childbearing potential
Not Eligible

You will not qualify if you...

  • Known cardiovascular or pulmonary disease, renal or liver dysfunction, immunological disease, diabetes, or active cancer that would render the study subject unfit for surgery
  • The planned surgical procedure is renal transplant or nephrectomy [note: partial nephrectomy is permitted provided that estimated glomerular filtration rate (eGFR) is not expected to fall below normal age-based limits]
  • Prior renal transplant
  • Impaired renal function defined as an estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m2
  • Impaired liver function defined as values > 1.5 times the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin, or < lower limit of normal (LLN) for albumin
  • Coagulopathy as manifested by international normalized ration (INR) > 1.3 (unless patient is on anti-coagulants)
  • Subjects with a marked baseline prolongation of QT/ corrected QT interval (QTc) interval (e.g., a QTc interval > 480 msec [CTCAE grade 1] using Fridericia's QT correction factor (14)
  • History of a clinically significant allergy or anaphylaxis to a component of the investigational medicinal product (IMP)
  • Known sensitivity to fluorescent light
  • Alcohol or recreational drug use that meets diagnostic and statistical manual of mental disorders (DSM5) criteria for moderate or severe substance use disorder
  • Pregnant or breastfeeding, or lack of effective contraception for at least one week post-surgery in male or female subjects with reproductive potential: for males, condom use; for females, oral contraceptives, diaphragm, or intrauterine devices (IUDs)
  • Any condition that the investigator considers to be potentially jeopardizing to the study subject's well-being or the study's objectives.
  • Participated in an interventional clinical research study within the previous 30 days.
  • The planned use of an 800 nm NIR fluorophore that is not Nizaracianine (e.g., indocyanine green or Pafolacianine) immediately before, during, or immediately after the planned abdominopelvic procedure.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Cedars Sinai Medical Center

Los Angeles, California, United States, 90048

Actively Recruiting

2

Board of Trustees of Leland Stanford Junior University

Redwood City, California, United States, 94063

Actively Recruiting

3

AdventHealth Orlando

Orlando, Florida, United States, 32803

Actively Recruiting

4

AdventHealth Tampa

Tampa, Florida, United States, 33613

Actively Recruiting

5

University of Massachusetts Chan Medical School

Worcester, Massachusetts, United States, 01655

Actively Recruiting

6

University Medical Center Groningen

Groningen, Netherlands, 9713 GZ Groningen

Actively Recruiting

7

Martini Hospital

Groningen, Netherlands, 9728 NT Groningen

Actively Recruiting

8

Leiden University Medical Centre (LUMC)

Leiden, Netherlands, 2333 ZA Leiden

Actively Recruiting

9

Erasmus Medical Centre

Rotterdam, Netherlands, 3015 GD Rotterdam

Actively Recruiting

10

Isala Zwolle

Zwolle, Netherlands, 8000 GK Zwolle

Actively Recruiting

Loading map...

Research Team

A

Alexander L Vahrmeijer, M.D., Ph.D.

CONTACT

C

Cedric Pesch, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here